“…The following RNAs were used: 800 pg of GR-Lef-CTA and GR-⌬NTcf3 (McLin et al 2007); 500 pg of pT7TS-Sfrp5, pCS107-Dkk1, pCS2-Sfrp2, pCS107-Crescent, pCS2 + Gsk3; 300 pg of pCS2-Dsh-myc (Sokol et al 1995), pCS2-Dsh-⌬PDZ(D2), and pCS2-Dsh-⌬DEP(D6) (Rothbächer et al 2000); 100 pg of pCS2 + sfrp5-UTR-GFP. The following plasmids were used: 250 pg of pCS2 + Xwnt8, pCS2 + Xwnt11, pCS2 + Xwnt2b, pCS2 + mwnt4, pCS107-Xwnt5b, pCS2 + Xwnt7b, pCS2 + pt--catenin, pCS2 + c.a.JNK (Liao et al 2006). Dex (1 µM; for GR constructs) and the following cell-soluble inhibitors were dissolved in DMSO and added to the media at stages 11-12; JNK inhibitor SP600125 (50-100 µM), Rac1 inhibitor NSC23766 (100-200 µM), Cdc42 inhibitor casin (50 µM), PKC inhibitor BIM (40 µM), Ca 2+ -dependant PKC inhibitor Go6976 (40 µM), G-protein inhibitor pertussis toxin (200-300 ng/mL), and CamKII inhibitor, KN-93 (20 µM).…”